Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Immunogenicity and Safety Study of GSK Biologicals' Candidate Malaria Vaccine (SB257049) Given at 6, 7.5 and 9 Months of Age in Co-administration With Measles, Rubella and Yellow Fever Vaccines Followed by a Booster of the Malaria Vaccine.

NCT02699099 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT02699099
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02699099 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Immunogenicity and Safety Study of GSK Biologicals' Candidate Malaria Vaccine (SB257049) Given at 6, 7.5 and 9 Months of Age in Co-administration With Measles, Rubella and Yellow Fever Vaccines Followed by a Booster of the Malaria Vaccine.
Lead sponsor
GlaxoSmithKline
Phase
Phase 3
Overall status
Completed
Start date
May 10, 2017
Completion date
October 7, 2020
Enrollment
699 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

malaria, malaria vaccines